CRISPR Therapeutics AG (NASDAQ:CRSP) shares, rose in value on Wednesday, July 09, with the stock price up by 9.60% to the previous day’s close as strong demand from buyers drove the stock to $60.08.
Actively observing the price movement in the last trading, the stock closed the session at $54.82, falling within a range of $55.8 and $60.13. The value of beta (5-year monthly) was 1.742. Referring to stock’s 52-week performance, its high was $63.68, and the low was $30.04. On the whole, CRSP has fluctuated by 43.53% over the past month.
With the market capitalization of CRISPR Therapeutics AG currently standing at about $5.19 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-06.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CRSP’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of CRSP currently trading nearly 27.58% and 45.35% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 85.23, while the 7-day volatility ratio is showing 6.67% which for the 30-day chart, stands at 5.82%. Furthermore, CRISPR Therapeutics AG (CRSP)’s beta value is 1.78.
A comparison of CRISPR Therapeutics AG (CRSP) with its peers suggests the former has fared considerably weaker in the market. CRSP showed an intraday change of 9.60% in last session, and over the past year, it grew by 52.64%%.
Data on historical trading for CRISPR Therapeutics AG (NASDAQ:CRSP) indicates that the trading volumes over the past 10 days have averaged 4.51 and over the past 3 months, they’ve averaged 2.61 million. According to company’s latest data on outstanding shares, there are 86.36 million shares outstanding.
Nearly 4.14% of CRISPR Therapeutics AG’s shares belong to company insiders and institutional investors own 69.28% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 21.41 million shares as on 2025-06-13, resulting in a short ratio of 9.74. According to the data, the short interest in CRISPR Therapeutics AG (CRSP) stood at 2819.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 21.07 million. The stock has risen by 13.15% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRSP stock heading into the next quarter.
